[Public Notice+] i-SENS Reports Q3 Operating Profit of 9.1 Billion KRW, Up 10% YoY

[Asia Economy Reporter Eunmo Koo] Biosensor specialist i-SENS reported a consolidated operating profit of 9.1 billion KRW for the third quarter, marking a 10% increase compared to the same period last year, as of the 28th. Sales during the same period rose 5% to 51.1 billion KRW.

An i-SENS representative explained, "Due to frequent typhoons, maritime shipments were delayed, causing September sales to be deferred to October. Reflecting this, we showed solid growth compared to the previous year."

i-SENS is preparing to secure next-generation technologies by strengthening its research and development (R&D) capabilities. The company is currently using its operating development expenses for the development of continuous glucose monitors and COVID-19 antibody measurement devices. Meanwhile, it is positive that the company is increasing overall profits through sales growth of existing product lines while investing in next-generation technology research costs.

An i-SENS representative stated, "To ensure the successful launch of the continuous glucose monitor, we are currently conducting clinical trials for researchers. Once this phase is completed, we plan to initiate approval clinical trials next year. Although the clinical schedule was delayed compared to the initial plan due to COVID-19, the company plans to continue preparations for commercialization by conducting pivotal clinical trials and investing in production facilities next year."

This content was produced with the assistance of AI translation services.